European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanib - carcinoma, renal cell - antineoplastic agents - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced rcc. treatment of advanced renal cell carcinoma.,

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tivozanib hydrochloride monohydrate 1.5mg equivalent to 1340 microgram tivozanib - capsule - 1340 mcg - active: tivozanib hydrochloride monohydrate 1.5mg equivalent to 1340 microgram tivozanib excipient: gelatin   iron oxide yellow   magnesium stearate mannitol titanium dioxide   - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-na?ve following disease progression after one prior treatment with cytokine therapy for advanced rcc.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tivozanib hydrochloride monohydrate 1mg equivalent to 890 microgram tivozanib - capsule - 890 mcg - active: tivozanib hydrochloride monohydrate 1mg equivalent to 890 microgram tivozanib excipient: gelatin   indigo carmine iron oxide yellow magnesium stearate mannitol titanium dioxide   - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-na?ve following disease progression after one prior treatment with cytokine therapy for advanced rcc.